These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25043337)

  • 1. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.
    Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
    J Clin Pharmacol; 2015 Jan; 55(1):93-103. PubMed ID: 25043337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
    Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
    J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
    Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
    Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
    Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
    Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
    CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
    Yang DS; Seong SJ; Yoon YR; Lim MS; Kwak KH; Lee SJ
    J Psychopharmacol; 2014 Apr; 28(4):341-8. PubMed ID: 24346811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
    Vermeulen A; Piotrovsky V; Ludwig EA
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of paliperidone versus risperidone and clinical effects.
    Nazirizadeh Y; Vogel F; Bader W; Haen E; Pfuhlmann B; Gründer G; Paulzen M; Schwarz M; Zernig G; Hiemke C
    Eur J Clin Pharmacol; 2010 Aug; 66(8):797-803. PubMed ID: 20358189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsphere delivery of Risperidone as an alternative to combination therapy.
    D'Souza S; Faraj J; DeLuca P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration.
    Elliott ES; Purvis TL; Nelson LA; Sommi RW
    J Clin Pharmacol; 2010 Jun; 50(6):721-4. PubMed ID: 20067943
    [No Abstract]   [Full Text] [Related]  

  • 16. Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone.
    Perlstein I; Merenlender Wagner A; Gomeni R; Lamson M; Harary E; Spiegelstein O; Kalmanczhelyi A; Tiver R; Loupe P; Levi M; Elgart A
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):865-877. PubMed ID: 35245409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
    Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
    Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].
    Mori T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):977-82. PubMed ID: 22187885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
    Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable.
    Medori R; Mannaert E; Gründer G
    Eur Neuropsychopharmacol; 2006 May; 16(4):233-40. PubMed ID: 16326078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.